The Netherlands Infection Control Market - Forecasts from 2020 to 2025
The Netherlands infection control market is expected to grow at a CAGR of 6.94% between 2019 and 2025. The presence of the varied type of hospitals in the Netherlands which include the major three types of hospitals namely academic hospitals, general hospitals, and teaching hospitals are offering heaps of opportunities for the market to proliferate in the forecast period owing to avoid hospital-associated infections in the forecast period. Prevalence of single or multiple diseases is affecting many men and women, hence they require specific treatments at different disease stages, further fueling the market demand in the forecast period. The presence of the elderly population in the country is projected to drive the market demand during the course of the forecast period. Furthermore, the establishment of advanced manufacturing operations by various multinational industries is further poised to augment the market demand in the forecast period.
The presence of single specific or multiple morbidities is estimated to fuel the market growth over the next five years.
The presence of single specific and multiple diseases in the elderly population in the Netherlands is affecting many men and women. This is providing an opportunity for the market to thrive in the forecast period as the global population ages along with the presence of ageing population in this country, the population will require treatment at different disease stages, hence, propelling the market growth in the forecast period. Some of the common diseases include osteoarthritis, diabetes, and coronary heart disease. In order to address these types of issues in the country, several cost-effective treatments in addition to the specialized treatments are available for improving the patient’s quality of life. This has further led to the declining of the disability of the geriatric population on a large scale. Also, special infection control measures need to be taken while dealing with the elderly population as these people are highly susceptible to infections due to their weak immune system. Furthermore, the prevalence of chronic diseases is expected to continue with the growing geriatric population in the country. Efforts are being taken for early disease detection and an improvement in the treatment of diseases. According to the National Institute for Public Health and the Environment, Netherlands, the number of people suffering from diabetes mellitus is estimated to rise from 0.8 million in 2011 to attain 1.2 million by the end of 2030. Hence, it is estimated that the number of people suffering from chronic diseases will grow from 5.3 million in 2011 to 7 million by 2030.
The setting of advanced manufacturing operations by the multinationals will augment the market demand in the forecast period.
The Netherlands holds a strong position as a manufacturing location in the European region for many companies from abroad, hence, the major multinational industries have their manufacturing operations in the country. The major ones include agriculture and life sciences, chemicals, and information technology. This is further encouraged by the supportive Holland’s corporate tax structure, a highly talented workforce holding fluency in multiple languages, along with exceptional engineering skills.
Segmentation:
The presence of single specific or multiple morbidities is estimated to fuel the market growth over the next five years.
The presence of single specific and multiple diseases in the elderly population in the Netherlands is affecting many men and women. This is providing an opportunity for the market to thrive in the forecast period as the global population ages along with the presence of ageing population in this country, the population will require treatment at different disease stages, hence, propelling the market growth in the forecast period. Some of the common diseases include osteoarthritis, diabetes, and coronary heart disease. In order to address these types of issues in the country, several cost-effective treatments in addition to the specialized treatments are available for improving the patient’s quality of life. This has further led to the declining of the disability of the geriatric population on a large scale. Also, special infection control measures need to be taken while dealing with the elderly population as these people are highly susceptible to infections due to their weak immune system. Furthermore, the prevalence of chronic diseases is expected to continue with the growing geriatric population in the country. Efforts are being taken for early disease detection and an improvement in the treatment of diseases. According to the National Institute for Public Health and the Environment, Netherlands, the number of people suffering from diabetes mellitus is estimated to rise from 0.8 million in 2011 to attain 1.2 million by the end of 2030. Hence, it is estimated that the number of people suffering from chronic diseases will grow from 5.3 million in 2011 to 7 million by 2030.
The setting of advanced manufacturing operations by the multinationals will augment the market demand in the forecast period.
The Netherlands holds a strong position as a manufacturing location in the European region for many companies from abroad, hence, the major multinational industries have their manufacturing operations in the country. The major ones include agriculture and life sciences, chemicals, and information technology. This is further encouraged by the supportive Holland’s corporate tax structure, a highly talented workforce holding fluency in multiple languages, along with exceptional engineering skills.
Segmentation:
- By Product
- Disinfectant
- Sterilization
- Low temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. THE NETHERLANDS INFECTION CONTROL MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Disinfectant
5.3. Sterilization
5.3.1. Low Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. THE NETHERLANDS INFECTION CONTROL MARKET ANALYSIS, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Medtronic
8.3. STERIS plc
8.4. B. Braun Melsungen AG
8.5. Sch?lke & Mayr GmbH
8.6. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. THE NETHERLANDS INFECTION CONTROL MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Disinfectant
5.3. Sterilization
5.3.1. Low Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. THE NETHERLANDS INFECTION CONTROL MARKET ANALYSIS, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Medtronic
8.3. STERIS plc
8.4. B. Braun Melsungen AG
8.5. Sch?lke & Mayr GmbH
8.6. List is not Exhaustive*
